ETOPOSIDE Side Effects

7023677-3 | Infusion Site Pain
on Sep 29, 2010 Male patient from UNITED STATES , 71 years of age, weighting 213.8 lb, was treated with Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: infusion site pain. Etoposide dosage: 219 Mg Every Day Iv. During the same period patient was treated with CARBOPLATIN (846 Once Iv) (View Carboplatin Review and Carboplatin Label ).

7018753-5 | Hepatitis B
Patient was taking Etoposide (View Usage). Patient had the following side effects: hepatitis b (What is hepatitis b?) on Sep 20, 2010 from TURKEY Additional patient health information: Female patient , 57 years of age, . Etoposide dosage: 200 Mg/m2/day. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (1.5 Mg/m2/day (max 2 Mg)) (View Vincristine Review and Vincristine Label ), DAUNORUBICIN HYDROCHLORIDE (25 Mg/m2/day) (View Daunorubicin Hydrochloride Review and Daunorubicin Hydrochloride Label ), ASPARAGINASE (5 000 U/m2/day) (View Asparaginase Review and Asparaginase Label ), PREDNISOLONE (60 Mg/m2/day) (View Prednisolone Review and Prednisolone Label ), CYCLOPHOSPHAMIDE (650 Mg/m2/day) (View Cyclophosphamide Review and Cyclophosphamide Label ), CYTARABINE (75 Mg/m2/day) (View Cytarabine Review and Cytarabine Label ).

7018751-1 | Encephalopathy
Adverse event was reported on Sep 24, 2010 by a Male patient taking Etoposide (View Usage) (Dosage: ) was diagnosed with b-cell lymphoma and. Location: FRANCE , 46 years of age, After Etoposide was administered, patient had the following side effects: encephalopathy. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ).

7014801-7 | Dysphagia, Neutropenia, Thrombocytopenia, Vomiting
on Sep 23, 2010 Male patient from INDIA , 72 years of age, weighting 97.00 lb, was diagnosed with non-small cell lung cancer stage iii, hypertension, dyspnoea, intermittent claudication and was treated with Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: dysphagia, neutropenia, thrombocytopenia, vomiting. Etoposide dosage: 70mg D1-d5.dose Reduced To 52.5mg D1-d5 From 16aug2010-ongoing.last Dose On 20aug2010. During the same period patient was treated with CISPLATIN (70mg .dose Reduced To 52.5mg D1-d8 From 16aug2010-ongoing.last Dose On 24aug2010) (View Cisplatin Review and Cisplatin Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), THEOPHYLLINE (View Theophylline Review and Theophylline Label ), GRANISETRON HCL (View Granisetron Hcl Review and Granisetron Hcl Label ), TRENTAL (View Trental Review and Trental Label ), ECOSPRIN (View Ecosprin Review and Ecosprin Label ), ATORVA (View Atorva Review and Atorva Label ). Patient was hospitalized.


7010339-1 | Eye Infection Fungal, Neutropenia, Pancreatitis Acute, Pancytopenia, Pneumonia, Pyrexia, Renal Failure Acute, Respiratory Disorder
on Sep 15, 2010 Male patient from GERMANY , 15 years of age, was treated with Etoposide (View Usage). Patient had the following side effects: eye infection fungal, neutropenia, pancreatitis acute, pancytopenia, pneumonia (What is pneumonia?), pyrexia, renal failure acute, respiratory disorder. Etoposide dosage: 150mgm2 Per Day. During the same period patient was treated with THIOGUANINE (40mgm2 Per Day) (View Thioguanine Review and Thioguanine Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), ARA C (40mgm2 Per Day) (View Ara-c Review and Ara-c Label ), IDARUBICIN HCL (7mgm2 Per Day) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MITOXANTRONE (10mgm2 Per Day) (View Mitoxantrone Review and Mitoxantrone Label ), AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ).

7009274-4 | Dysphagia, Neutropenia, Thrombocytopenia, Vomiting
Patient was taking Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: dysphagia, neutropenia, thrombocytopenia, vomiting on Sep 14, 2010 from INDIA Additional patient health information: Male patient , 72 years of age, weighting 97.00 lb, was diagnosed with non-small cell lung cancer stage iii, hypertension, dyspnoea, intermittent claudication and. Etoposide dosage: 70mg D1-d5.dose Reduced To 52.5mg D1-d5 From 16aug2010-ongoing.last Dose On 20aug2010. During the same period patient was treated with CISPLATIN (70mg .dose Reduced To 52.5mg D1-d8 From 16aug2010-ongoing.last Dose On 24aug2010) (View Cisplatin Review and Cisplatin Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), THEOPHYLLINE (View Theophylline Review and Theophylline Label ), GRANISETRON HCL (View Granisetron Hcl Review and Granisetron Hcl Label ), TRENTAL (View Trental Review and Trental Label ), ECOSPRIN (View Ecosprin Review and Ecosprin Label ), ATORVA (View Atorva Review and Atorva Label ). Patient was hospitalized.

7008774-0 | Confusional State, Headache, Metastases To Lung, Nausea, Somnolence, Testicular Cancer Metastatic
Adverse event was reported on Sep 07, 2010 by a Male patient taking Etoposide (View Usage) (Dosage: ) was diagnosed with chronic myeloid leukaemia and. Location: POLAND , 30 years of age, Patient experienced the following unwanted or unexpected effects: confusional state, headache (What is headache?), metastases to lung, nausea (What is nausea?), somnolence, testicular cancer metastatic. During the same period patient was treated with IMATINIB (IMATINIB) (IMATINIB) ((400 Mg/day)) (View Imatinib (imatinib) (imatinib) Review and Imatinib (imatinib) (imatinib) Label ), IFOSFAMIDE (IFOSFAMIDE) (IFOSFAMIDE) (View Ifosfamide (ifosfamide) (ifosfamide) Review and Ifosfamide (ifosfamide) (ifosfamide) Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

6992228-1 | Blood Chloride Decreased, Blood Magnesium Decreased, Blood Sodium Decreased, Dysphagia, Neutropenia, Thrombocytopenia, Vomiting
on Sep 14, 2010 Male patient from INDIA , 72 years of age, weighting 97.00 lb, was diagnosed with non-small cell lung cancer stage iii, hypertension, dyspnoea, intermittent claudication and was treated with Etoposide (View Usage). Patient had the following side effects: blood chloride decreased, blood magnesium decreased, blood sodium decreased, dysphagia, neutropenia, thrombocytopenia, vomiting. Etoposide dosage: 70mg D1-d5.dose Reduced To 52.5mg D1-d5 From 16aug2010-ongoing.last Dose On 20aug2010. During the same period patient was treated with CISPLATIN (70mg .dose Reduced To 52.5mg D1-d8 From 16aug2010-ongoing.last Dose On 24aug2010) (View Cisplatin Review and Cisplatin Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), THEOPHYLLINE (View Theophylline Review and Theophylline Label ), GRANISETRON HCL (View Granisetron Hcl Review and Granisetron Hcl Label ), TRENTAL (View Trental Review and Trental Label ), ECOSPRIN (View Ecosprin Review and Ecosprin Label ), ATORVA (View Atorva Review and Atorva Label ). Patient was hospitalized.

6984734-0 | Abdominal Pain, Cough, Haemoptysis, Hypertension, Hypotension, Left Ventricular Dysfunction, Myocardial Infarction, Pulmonary Oedema, Respiratory Failure
on Sep 03, 2010 Male patient from UNITED STATES , child 7 years of age, weighting 52.91 lb, was diagnosed with lymphohistiocytosis and was treated with Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), cough, haemoptysis, hypertension, hypotension, left ventricular dysfunction, myocardial infarction, pulmonary oedema, respiratory failure. Etoposide dosage: 150gm/m2 X 2 Weekly. Patient was hospitalized.

6977069-3 | Activated Partial Thromboplastin Time Prolonged, Acute Respiratory Distress Syndrome, Anaemia, Antithrombin Iii Decreased, Blood Fibrinogen Increased, Blood Pressure Decreased, Bone Marrow Failure, Fibrin D Dimer Increased, Hepatic Function Abnormal
Patient was taking Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: activated partial thromboplastin time prolonged, acute respiratory distress syndrome, anaemia, antithrombin iii decreased, blood fibrinogen increased, blood pressure decreased, bone marrow failure, fibrin d dimer increased, hepatic function abnormal on Sep 01, 2010 from JAPAN Additional patient health information: Male patient , 29 years of age, was diagnosed with acute lymphocytic leukaemia and. Etoposide dosage: . During the same period patient was treated with CYTARABINE (Inj) (View Cytarabine Review and Cytarabine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6963938-7 | Febrile Neutropenia, Pneumonia
Adverse event was reported on Aug 20, 2010 by a Male patient taking Etoposide (View Usage) (Dosage: 50mg/m2 Iv Days 1-5 Every 4 Weeks) was diagnosed with non-small cell lung cancer stage iii and. Location: , 60 years of age, weighting 196.2 lb, Patient had the following side effects: febrile neutropenia, pneumonia (What is pneumonia?). Patient was hospitalized.

6961556-8 | Myocardial Infarction
on Aug 18, 2010 Male patient from UNITED STATES , child 7 years of age, weighting 50.71 lb, was diagnosed with lymphohistiocytosis and was treated with Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: myocardial infarction. Etoposide dosage: 150 Mg/m2 Twice Weekly (body Surface Area 0.89 M2). During the same period patient was treated with DEXAMETHASONE (10 Mg/m2 Per Day In Two Divided Doses) (View Dexamethasone Review and Dexamethasone Label ), CYCLOSPORINE (Twice Daily Ciclosporin 1.5 Mg/kg Per Dose) (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

6943518-X | Neoplasm Skin, Oesophageal Squamous Cell Carcinoma, Sweat Gland Tumour
on Aug 13, 2010 Male patient from UNITED KINGDOM , 32 years of age, was diagnosed with teratoma of testis, chronic graft versus host disease, acute graft versus host disease, acute myeloid leukaemia and was treated with Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: neoplasm skin, oesophageal squamous cell carcinoma, sweat gland tumour. Etoposide dosage: . During the same period patient was treated with BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

6942802-3 | Cardiomyopathy
Patient was taking Etoposide (View Usage). Patient had the following side effects: cardiomyopathy (What is cardiomyopathy?) on Aug 17, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 81 years of age, weighting 132.3 lb, was diagnosed with non-hodgkin's lymphoma and. Etoposide dosage: . During the same period patient was treated with MITOXANTRONE (View Mitoxantrone Review and Mitoxantrone Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ).

6938040-0 | Myocardial Infarction
Adverse event was reported on Aug 16, 2010 by a Male patient taking Etoposide (View Usage) (Dosage: 150 Mg/m2 Twice Weekly) was diagnosed with lymphohistiocytosis and. Location: UNITED STATES , child 7 years of age, After Etoposide was administered, patient had the following side effects: myocardial infarction. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6937768-6 | Myocardial Infarction, Respiratory Failure
on Aug 20, 2010 Male patient from UNITED STATES , child 7 years of age, was diagnosed with histiocytosis haematophagic and was treated with Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: myocardial infarction, respiratory failure. Etoposide dosage: Total Dose: 4. During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6937098-2 | Dyspnoea, Hypoxia, Respiratory Tract Infection Fungal
on Aug 11, 2010 Female patient from UNITED STATES , 19 years of age, weighting 162.0 lb, was diagnosed with acute myeloid leukaemia and was treated with Etoposide (View Usage). Patient had the following side effects: dyspnoea, hypoxia, respiratory tract infection fungal. Etoposide dosage: 150mg, 1x/day For 7 Days, Iv. During the same period patient was treated with ANTIBACTERIAL MEROPENEM (View Antibacterial Meropenem Review and Antibacterial Meropenem Label ), ANTIBACTERIAL CIPROFLOXACIN (View Antibacterial Ciprofloxacin Review and Antibacterial Ciprofloxacin Label ), ANTIFUNGAL FLUCONAZOLE (View Antifungal Fluconazole Review and Antifungal Fluconazole Label ), ANTIFUNGAL VANCOMYCIN (View Antifungal Vancomycin Review and Antifungal Vancomycin Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), ANTIFUNGAL AMPHOTERICINE B (View Antifungal Amphotericine B Review and Antifungal Amphotericine B Label ), LIPOSOME (AMBISOME) (View Liposome (ambisome) Review and Liposome (ambisome) Label ). Patient was hospitalized.

6907683-2 | Enterococcus Test Positive, Febrile Neutropenia, Malignant Neoplasm Progression, Non-small Cell Lung Cancer Stage Iii, Pneumonia
Patient was taking Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: enterococcus test positive, febrile neutropenia, malignant neoplasm progression, non-small cell lung cancer stage iii, pneumonia (What is pneumonia?) on Jun 17, 2010 from UNITED STATES Additional patient health information: Male patient , 60 years of age, weighting 196.2 lb, was diagnosed with non-small cell lung cancer stage iii and. Etoposide dosage: 50mg/m2 Iv Days 1-5 Every 4 Weeks. Patient was hospitalized.

6905386-1 | Abdominal Pain, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Lactate Dehydrogenase Increased, Cardiac Failure, Cardiotoxicity, Fluid Overload, Haemoglobin Decreased, Haemoptysis
Adverse event was reported on Jul 23, 2010 by a Male patient taking Etoposide (View Usage) (Dosage: 150 Mg Per Square Meter, Twice Weekly,) was diagnosed with lymphohistiocytosis and. Location: UNITED STATES , child 7 years of age, weighting 51.81 lb, Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, cardiac failure, cardiotoxicity, fluid overload, haemoglobin decreased, haemoptysis. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), DIURETICS (View Diuretics Review and Diuretics Label ), VASOCONSTRICTOR (View Vasoconstrictor Review and Vasoconstrictor Label ).

6881430-5 | Cough, Dysgeusia, Rash
on Jul 28, 2010 Male patient from UNITED STATES , child 2 years of age, weighting 23.59 lb, was diagnosed with neuroblastoma (What is neuroblastoma?) and was treated with Etoposide (View Usage). Patient had the following side effects: cough, dysgeusia, rash (What is rash?). Etoposide dosage: 69mg Q24h Iv. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ).

6869879-8 | Atrial Fibrillation, Blood Sodium Decreased, C-reactive Protein Increased, Fall
on Jul 14, 2010 Male patient from UNITED STATES , 70 years of age, weighting 189.6 lb, was diagnosed with non-small cell lung cancer stage iii and was treated with Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), blood sodium decreased, c-reactive protein increased, fall (What is fall?). Etoposide dosage: 108mg Iv. Patient was hospitalized.

6865045-0 | Coronary Artery Thrombosis
Patient was taking Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: coronary artery thrombosis on Jul 05, 2010 from TURKEY Additional patient health information: Female patient , 43 years of age, was diagnosed with testis cancer and. Etoposide dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ).

6843057-0 | Abdominal Pain, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Lactate Dehydrogenase Increased, Cardiotoxicity, Chest Pain, Cough, Haemoptysis, Hypertension
Adverse event was reported on Apr 05, 2010 by a Male patient taking Etoposide (View Usage) (Dosage: ) was diagnosed with histiocytosis haematophagic and. Location: UNITED STATES , child 7 years of age, weighting 51.81 lb, Patient had the following side effects: abdominal pain (What is abdominal pain?), alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, cardiotoxicity, chest pain (What is chest pain?), cough, haemoptysis, hypertension. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), CYCLOSPORIN (CICLOSPORIN) (CICLOSPORIN) (View Cyclosporin (ciclosporin) (ciclosporin) Review and Cyclosporin (ciclosporin) (ciclosporin) Label ). Patient was hospitalized.

6839235-7 | Blood Sodium Decreased, Facial Pain, Febrile Neutropenia, Haemoglobin Decreased, Platelet Count Decreased, White Blood Cell Count Decreased
on Jun 22, 2010 Male patient from UNITED KINGDOM , 28 years of age, was treated with Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: blood sodium decreased, facial pain, febrile neutropenia, haemoglobin decreased, platelet count decreased, white blood cell count decreased. Etoposide dosage: 330 Mg Milligram(s), Intravenous; 20% Dose Reduction. During the same period patient was treated with CISPLATIN (99 Mg Milligram(s), Intravenous) (View Cisplatin Review and Cisplatin Label ), NEULASTA (6 Mg Milligram(s), Subcutaneous; 30?g Microgram(s) Subcutaneous) (View Neulasta Review and Neulasta Label ), APREPITANT (View Aprepitant Review and Aprepitant Label ), BLEOMYCIN (View Bleomycin Review and Bleomycin Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ). Patient was hospitalized.

6830555-9 | Atrial Fibrillation, Blood Sodium Decreased
on Jun 29, 2010 Male patient from UNITED STATES , 70 years of age, weighting 189.6 lb, was diagnosed with non-small cell lung cancer stage iii and was treated with Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: atrial fibrillation (What is atrial fibrillation?), blood sodium decreased. Etoposide dosage: 108mg/iv. Patient was hospitalized.

6816523-1 | Gastrointestinal Perforation
Patient was taking Etoposide (View Usage). Patient had the following side effects: gastrointestinal perforation on Jun 23, 2010 from UNITED STATES Additional patient health information: Male patient , 42 years of age, weighting 198.4 lb, was diagnosed with non-small cell lung cancer and. Etoposide dosage: 50mg/m2. Patient was hospitalized.

6803645-4 | Gastrointestinal Perforation
Adverse event was reported on Jun 23, 2010 by a Male patient taking Etoposide (View Usage) (Dosage: ) was diagnosed with non-small cell lung cancer, pain (What is pain?), oedema and. Location: GERMANY , 42 years of age, weighting 198.4 lb, After Etoposide was administered, patient had the following side effects: gastrointestinal perforation. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), VERGENTAN (View Vergentan Review and Vergentan Label ), MCP (View Mcp Review and Mcp Label ), FORTECORTIN (View Fortecortin Review and Fortecortin Label ), TOREM (View Torem Review and Torem Label ), AMITRIPTYLINE HCL (View Amitriptyline Hcl Review and Amitriptyline Hcl Label ). Patient was hospitalized.

6797276-2 | Acute Graft Versus Host Disease, Acute Myeloid Leukaemia, Bone Marrow Transplant, Chronic Graft Versus Host Disease, Neoplasm Skin, Oesophageal Squamous Cell Carcinoma, Photosensitivity Reaction, Porokeratosis, Sweat Gland Tumour
on Jun 08, 2010 Male patient from UNITED KINGDOM , 28 years of age, was diagnosed with teratoma of testis, stem cell transplant, acute graft versus host disease, acute myeloid leukaemia and was treated with Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, acute myeloid leukaemia, bone marrow transplant (What is bone marrow transplant?), chronic graft versus host disease, neoplasm skin, oesophageal squamous cell carcinoma, photosensitivity reaction, porokeratosis, sweat gland tumour. Etoposide dosage: . During the same period patient was treated with MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6794444-0 | Tumour Lysis Syndrome
on Jun 21, 2010 Male patient from FRANCE , 50 years of age, was diagnosed with adult t-cell lymphoma/leukaemia and was treated with Etoposide (View Usage). Patient had the following side effects: tumour lysis syndrome. Etoposide dosage: . During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), INTERFERON ALFA 2B (View Interferon Alfa-2b Review and Interferon Alfa-2b Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).

6774716-6 | Leukopenia, Ovarian Cyst, Septic Shock, Uterine Perforation
Patient was taking Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: leukopenia, ovarian cyst (What is ovarian cyst?), septic shock, uterine perforation on Jun 07, 2010 from SWITZERLAND Additional patient health information: Female patient , 25 years of age, . Etoposide dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), DACTINOMYCIN (View Dactinomycin Review and Dactinomycin Label ). Patient was hospitalized.

6768872-3 | Gastrointestinal Perforation
Adverse event was reported on Jun 08, 2010 by a Male patient taking Etoposide (View Usage) (Dosage: 50 Mg/m2) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , 42 years of age, weighting 198.4 lb, Patient experienced the following unwanted or unexpected effects: gastrointestinal perforation. Patient was hospitalized.

6768354-9 | Gastrointestinal Perforation
on Jun 08, 2010 Male patient from GERMANY , 42 years of age, weighting 198.4 lb, was diagnosed with non-small cell lung cancer, pain (What is pain?), oedema and was treated with Etoposide (View Usage). Patient had the following side effects: gastrointestinal perforation. Etoposide dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), VERGENTAN (View Vergentan Review and Vergentan Label ), MCP (View Mcp Review and Mcp Label ), FORTECORTIN (View Fortecortin Review and Fortecortin Label ), TOREM (View Torem Review and Torem Label ), AMITRIPTYLINE HCL (View Amitriptyline Hcl Review and Amitriptyline Hcl Label ). Patient was hospitalized.

6763849-6 | Brain Compression, Brain Herniation, Cerebral Infarction, Cerebral Thrombosis, Depressed Level Of Consciousness, Hydrocephalus, Lung Infection, Lung Infiltration, Lung Neoplasm
on Jun 01, 2010 Female patient from UNITED STATES , 14 years of age, was diagnosed with ewing's sarcoma and was treated with Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: brain compression, brain herniation, cerebral infarction, cerebral thrombosis, depressed level of consciousness, hydrocephalus (What is hydrocephalus?), lung infection, lung infiltration, lung neoplasm. Etoposide dosage: Iv. Patient was hospitalized.

6745039-6 | Fusarium Infection, Neutropenia
Patient was taking Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: fusarium infection, neutropenia on May 17, 2010 from ITALY Additional patient health information: Male patient , child 8 years of age, was diagnosed with myeloid leukaemia and. Etoposide dosage: High Dose. During the same period patient was treated with CYTARABINE (High Dose) (View Cytarabine Review and Cytarabine Label ).

6737837-X | Acute Myeloid Leukaemia
Adverse event was reported on May 07, 2010 by a Male patient taking Etoposide (View Usage) (Dosage: ) was diagnosed with ewing's sarcoma metastatic and. Location: UNITED STATES , 17 years of age, Patient had the following side effects: acute myeloid leukaemia. During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ).

6736864-6 | Apnoea, Blood Ph Decreased, Bone Sarcoma, Cardiac Arrest, Disorientation, Electromechanical Dissociation, Encephalopathy, Hyperhidrosis, Hyperkalaemia
on May 20, 2010 Male patient from UNITED STATES , weighting 147.9 lb, was treated with Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: apnoea, blood ph decreased, bone sarcoma, cardiac arrest (What is cardiac arrest?), disorientation, electromechanical dissociation, encephalopathy, hyperhidrosis, hyperkalaemia. Etoposide dosage: 400 Mg. During the same period patient was treated with IFOSFAMIDE (11000 Mg) (View Ifosfamide Review and Ifosfamide Label ). Patient was hospitalized.

6704215-9 | Carotid Artery Thrombosis, Pulmonary Embolism
on Apr 20, 2010 Male patient from UNITED KINGDOM , 36 years of age, was diagnosed with testis cancer and was treated with Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: carotid artery thrombosis, pulmonary embolism (What is pulmonary embolism?). Etoposide dosage: Unk. During the same period patient was treated with CISPLATIN (Unk) (View Cisplatin Review and Cisplatin Label ), BLEOMYCIN (Unk) (View Bleomycin Review and Bleomycin Label ).

6704093-8 | Aspergillosis
Patient was taking Etoposide (View Usage). Patient had the following side effects: aspergillosis on Apr 19, 2010 from CHINA Additional patient health information: Female patient , child 2 years of age, was diagnosed with acute myeloid leukaemia and. Etoposide dosage: Unk. During the same period patient was treated with DAUNORUBICIN HCL (Unk) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), CYTOSINE ARABINOSIDE (Unk) (View Cytosine Arabinoside Review and Cytosine Arabinoside Label ).

6695832-3 | Aspergillosis, Bone Marrow Failure, Pancytopenia
Adverse event was reported on Jul 24, 2009 by a Male patient taking Etoposide (View Usage) (Dosage: ) . Location: UNITED STATES , child 7 years of age, After Etoposide was administered, patient had the following side effects: aspergillosis, bone marrow failure, pancytopenia.

6689305-1 | Asthenia, Chest Discomfort, Dialysis, Haematoma, Haemoglobin Decreased, Headache, Hepatic Function Abnormal, Hypoxia, Malignant Neoplasm Progression
on Apr 06, 2010 Female patient from UNITED STATES , 49 years of age, weighting 154.3 lb, was diagnosed with non-small cell lung cancer stage iii and was treated with Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, chest discomfort, dialysis (What is dialysis?), haematoma, haemoglobin decreased, headache (What is headache?), hepatic function abnormal, hypoxia, malignant neoplasm progression. Etoposide dosage: 50mg/m2, Days 1-5. Patient was hospitalized.

6684840-4 | Abdominal Pain, Anaemia, Febrile Neutropenia, Hypokalaemia
on Apr 12, 2010 Female patient from UNITED STATES , 65 years of age, weighting 169.8 lb, was diagnosed with prophylaxis of nausea and vomiting, hypertension, hyperlipidaemia, gastrooesophageal reflux disease and was treated with Etoposide (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), anaemia, febrile neutropenia, hypokalaemia. Etoposide dosage: Day 1-3 29oct09-03nov09,(5days) 08jan10;inj.. During the same period patient was treated with CISPLATIN (08jan10) (View Cisplatin Review and Cisplatin Label ), LORAZEPAM (0.5-1 Mg(as Required);19nov09-19nov09(2mg)(1mg,2 In 1 D);23nov09(1mg,once).) (View Lorazepam Review and Lorazepam Label ), PROCHLORPERAZINE EDISYLATE (Dosing Frequency=q6h Prn) (View Prochlorperazine Edisylate Review and Prochlorperazine Edisylate Label ), HYDROCHLOROTHIAZIDE (1998-07nov(11 Yrs) 10nov09-ong) (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), ONDANSETRON (2oct(8mg),29oct(12mg),30sep(12mg)31oct,20,21,22nov,11,12,13dec09,4,5,6jan10(16mg Once).) (View Ondansetron Review and Ondansetron Label ), EZETIMIBE (View Ezetimibe Review and Ezetimibe Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

6676143-9 | Acute Myeloid Leukaemia
Patient was taking Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: acute myeloid leukaemia on Apr 05, 2010 from UNITED STATES Additional patient health information: Male patient , 39 years of age, was diagnosed with diffuse large b-cell lymphoma and. Etoposide dosage: . During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ). Patient was hospitalized.

6674121-7 | Abdominal Pain, Anaemia, Febrile Neutropenia, Hypokalaemia, Nausea
Adverse event was reported on Apr 06, 2010 by a Female patient taking Etoposide (View Usage) (Dosage: Day 1-3 29oct09-03nov09,(5days) 08jan10) was diagnosed with prophylaxis of nausea and vomiting, hypertension, hyperlipidaemia, gastrooesophageal reflux disease and. Location: UNITED STATES , 65 years of age, weighting 169.8 lb, Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), anaemia, febrile neutropenia, hypokalaemia, nausea (What is nausea?). During the same period patient was treated with CISPLATIN (08jan10) (View Cisplatin Review and Cisplatin Label ), LORAZEPAM (0.5-1 Mg(as Required);19nov09-19nov09(2mg)(1mg,2 In 1 D)) (View Lorazepam Review and Lorazepam Label ), PROCHLORPERAZINE EDISYLATE (Dosing Frequency=q6h Prn) (View Prochlorperazine Edisylate Review and Prochlorperazine Edisylate Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), EZETIMIBE (View Ezetimibe Review and Ezetimibe Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

6671080-8 | Fibrosis, Sphincter Of Oddi Dysfunction
on Mar 24, 2010 Male patient from TURKEY , 62 years of age, was treated with Etoposide (View Usage). Patient had the following side effects: fibrosis, sphincter of oddi dysfunction. Etoposide dosage: 100 Mg/m2, 3 Days Every 21 Days. During the same period patient was treated with CISPLATIN (80 Mg/m2, First Day) (View Cisplatin Review and Cisplatin Label ).

6671079-1 | Superior Vena Caval Occlusion
on Mar 31, 2010 Male patient from TURKEY , 51 years of age, was treated with Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: superior vena caval occlusion. Etoposide dosage: Unk. During the same period patient was treated with CISPLATIN (Unk) (View Cisplatin Review and Cisplatin Label ).

6654019-0 | Agitation, Aphasia, Carotid Artery Thrombosis, Encephalitis, Haemorrhagic Transformation Stroke, Hemiparesis, Hemiplegia, Ischaemic Stroke, Lung Cancer Metastatic
Patient was taking Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: agitation, aphasia (What is aphasia?), carotid artery thrombosis, encephalitis (What is encephalitis?), haemorrhagic transformation stroke, hemiparesis, hemiplegia, ischaemic stroke, lung cancer metastatic on Mar 15, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 36 years of age, was diagnosed with germ cell cancer and. Etoposide dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ).

6644255-1 | Acute Respiratory Distress Syndrome, Anaemia, Neutropenia, Septic Shock, Thrombocytopenia
Adverse event was reported on Mar 02, 2010 by a Male patient taking Etoposide (View Usage) (Dosage: 125 Mg/m2, Total 4 Doses) was diagnosed with acute promyelocytic leukaemia and. Location: AUSTRIA , 13 years of age, Patient had the following side effects: acute respiratory distress syndrome, anaemia, neutropenia, septic shock, thrombocytopenia. During the same period patient was treated with CYTARABINE (3000 Mg/m2, Total 6 Doses) (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

6641495-2 | Acute Respiratory Distress Syndrome
on Mar 05, 2010 Male patient from AUSTRIA , 13 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Etoposide (View Usage). After Etoposide was administered, patient had the following side effects: acute respiratory distress syndrome. Etoposide dosage: 125 Mg/m2, Daily. During the same period patient was treated with CYTARABINE (3 G/m2 X 6 Doses) (View Cytarabine Review and Cytarabine Label ), ISOTRETINOIN (View Isotretinoin Review and Isotretinoin Label ).

6640596-2 | Abdominal Pain, Anaemia, Febrile Neutropenia, Hypokalaemia, Nausea
on Mar 15, 2010 Female patient from UNITED STATES , 65 years of age, weighting 169.8 lb, was diagnosed with prophylaxis of nausea and vomiting, hypertension, hyperlipidaemia, gastrooesophageal reflux disease and was treated with Etoposide (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), anaemia, febrile neutropenia, hypokalaemia, nausea (What is nausea?). Etoposide dosage: Day 1-3 29oct09-03nov09, 08jan10. During the same period patient was treated with CISPLATIN (08jan10) (View Cisplatin Review and Cisplatin Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), PROCHLORPERAZINE EDISYLATE (Dosing Frequency=q6h Prn) (View Prochlorperazine Edisylate Review and Prochlorperazine Edisylate Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), EZETIMIBE (View Ezetimibe Review and Ezetimibe Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

6639881-X | Abdominal Pain, Nausea
Patient was taking Etoposide (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), nausea (What is nausea?) on Mar 15, 2010 from UNITED STATES Additional patient health information: Female patient , 65 years of age, weighting 169.8 lb, was diagnosed with prophylaxis of nausea and vomiting and. Etoposide dosage: 29oct09-03nov09. During the same period patient was treated with CISPLATIN (29oct09-03nov09) (View Cisplatin Review and Cisplatin Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), PROCHLORPERAZINE EDISYLATE (Q6h) (View Prochlorperazine Edisylate Review and Prochlorperazine Edisylate Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), ONDANSETRON (02oct09-ong, 8mg, 29oct09-29oct09, 12mg, 30oct09-30oct09, 12mg, 31oct09-31oct09, 16mg) (View Ondansetron Review and Ondansetron Label ), EZETIMIBE (View Ezetimibe Review and Ezetimibe Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.